Beijing, China，Recently –  Gan & Lee Pharmaceuticals (hereinafter referred to as Gan & Lee, stock code: 603087.SH) announced that its insulin aspart injection, developed in collaboration with a local pharmaceutical company in Argentina, has received approval from the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, ANMAT. This approval marks another key milestone for the company in Argentina, following the previous approval of insulin glargine, and further enriches the company's product portfolio in the region.

According to the latest data from the International Diabetes Federation's (IDF) Diabetes Atlas, Argentina's adult diabetes population surpassed 4.34 million in 2024, with a prevalence rate of 14.1%. In Argentina, the average annual diabetes-related healthcare expenditure per person is around $3,500, significantly higher than the regional Latin American average¹. This highlights the critical diabetes burden faced by Argentina, a key healthcare market in Latin America. The data highlights the growing demand for high-quality, cost-effective insulin therapies in the country. To address this pressing need, Gan & Lee has been strategically expanding its presence in the Argentine market, aiming to provide effective solutions.

The newly approved insulin aspart injection, with its high-quality formulation, cost-effective pricing, and reliable supply system, is expected to improve the accessibility of diabetes medication for Argentine patients. Notably, Gan & Lee has partnered with local companies for local filling, which will shorten the supply cycle and further strengthen the product's availability in the Argentine market. This approach not only supports the company's commitment to ensuring supply but also focuses on ensuring stability, with the goal of creating a reliable and sustainable insulin supply system that allows more patients to receive consistent and ongoing treatment.

This successful market entry in Argentina provides strong momentum for the company's strategic expansion across Latin America's growing healthcare markets. Looking ahead, Gan & Lee will continue to uphold its patient-centric philosophy and work tirelessly to enhance the global accessibility of high-quality, innovative medicines, ensuring that patients in diverse regions can benefit from better diabetes treatment solutions.

Reference:

1. IDF Diabetes Atlas 11th edition 2025. Available at: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.